Drug updated on 4/16/2024
| Dosage Form | Injection (intravenous; 1 g of sulbactam for injection [1 clear single-dose vial] and 0.5 g of durlobactam for injection [2 amber single-dose vials]) |
| Drug Class | Beta lactamase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
Summary
- Sulbactam and durlobactam (Xacduro) is indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in patients 18 years or older.
- The information on this drug was derived from a single systematic review/meta-analysis study, focusing on its potential effectiveness against infections caused by A. baumannii, including carbapenem-resistant strains.
- Combining durlobactam with sulbactam enhances the activity against sulbactam-resistant isolates and effectively reverses their resistance, making them susceptible again; this suggests that Xacduro could be a significant option for dealing with multidrug-resistant A. baumannii strains.
- While the systematic review indicates that Xacduro may be an effective therapeutic option for treating infections caused by multidrug-resistant A. baumannii, it emphasizes the need for future clinical trials to firmly establish its safety and efficacy.
- No direct comparisons between Xacduro and other antimicrobial agents were provided in terms of safety and effectiveness; however, its implied advantage lies in its specific action towards reversing resistance among certain HABP/VABP causing bacteria, which are difficult to manage with existing therapies.
- Although specified as suitable for patients aged 18 years or older suffering from HABP/VABP due to multidrug-resistant A. baumannii infection, no further details regarding different population types or subgroup considerations were mentioned.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Xacduro (sulbactam, durlobactam) Prescribing Information. | 2023 | Entasis Therapeutics Ltd., an affiliate of Innoviva Specialty Therapeutics, Waltham, MA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Sulbactam-durlobactam, a novel drug for the treatment of multidrug-resistant acinetobacter baumannii infections - a systematic review. | 2024 | Infectious Disorders Drug Targets |